MX389845B - 1-metilnicotinamida para el tratamiento de enfermedades asociadas con la proteína c reactiva. - Google Patents
1-metilnicotinamida para el tratamiento de enfermedades asociadas con la proteína c reactiva.Info
- Publication number
- MX389845B MX389845B MX2019000721A MX2019000721A MX389845B MX 389845 B MX389845 B MX 389845B MX 2019000721 A MX2019000721 A MX 2019000721A MX 2019000721 A MX2019000721 A MX 2019000721A MX 389845 B MX389845 B MX 389845B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methylnicotinamide
- mna
- blood
- pharmaceutically acceptable
- Prior art date
Links
- LDHMAVIPBRSVRG-UHFFFAOYSA-O 1-methylnicotinamide Chemical compound C[N+]1=CC=CC(C(N)=O)=C1 LDHMAVIPBRSVRG-UHFFFAOYSA-O 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 108010074051 C-Reactive Protein Proteins 0.000 title 1
- 102100032752 C-reactive protein Human genes 0.000 title 1
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 abstract 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 201000003068 rheumatic fever Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000022218 streptococcal pneumonia Diseases 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363712P | 2016-07-18 | 2016-07-18 | |
| PCT/IB2017/054293 WO2018015861A1 (en) | 2016-07-18 | 2017-07-16 | 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000721A MX2019000721A (es) | 2019-06-10 |
| MX389845B true MX389845B (es) | 2025-03-20 |
Family
ID=59399457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000721A MX389845B (es) | 2016-07-18 | 2017-07-16 | 1-metilnicotinamida para el tratamiento de enfermedades asociadas con la proteína c reactiva. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190282560A1 (https=) |
| EP (1) | EP3484475B1 (https=) |
| JP (1) | JP2019521160A (https=) |
| CN (1) | CN109562108A (https=) |
| AU (1) | AU2017298648B2 (https=) |
| DK (1) | DK3484475T3 (https=) |
| ES (1) | ES2967074T3 (https=) |
| FI (1) | FI3484475T3 (https=) |
| MX (1) | MX389845B (https=) |
| PL (1) | PL3484475T3 (https=) |
| RU (1) | RU2744615C2 (https=) |
| WO (1) | WO2018015861A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020115765A1 (en) | 2018-12-05 | 2020-06-11 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome |
| CN112294786A (zh) * | 2019-08-01 | 2021-02-02 | 深圳大学 | 一种含乙胺丁醇与他汀类药物的抗结核组合药物 |
| WO2021205341A1 (en) | 2020-04-07 | 2021-10-14 | Pharmena S.A. | 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases |
| WO2022047730A1 (en) * | 2020-09-04 | 2022-03-10 | Shanghai Pharmaceuticals Holding Co., Ltd. | Methods to treat inflammatory bowel disease |
| EP4213821A2 (en) * | 2020-09-21 | 2023-07-26 | The Regents of the University of California | Immunological effects of metabolites |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT131118B (de) | 1929-04-19 | 1933-01-10 | Ig Farbenindustrie Ag | Verfahren zur Darstellung von N-Methylpyridiniumchlorid. |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3614408A (en) | 1969-02-20 | 1971-10-19 | British Petroleum Co | Waveform analyzing system, particularly for chromatographs, wherein the waveform is integrated between selected peaks and valleys |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4115390A (en) | 1977-08-19 | 1978-09-19 | Nardi John C | Method for the preparation of 1-alkyl pyridinium chlorides |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US7030152B1 (en) | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
| PL364348A1 (en) * | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| WO2006024545A1 (en) * | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
| ATE548035T1 (de) * | 2005-07-11 | 2012-03-15 | Cortria Corp | Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat |
| CA2629913A1 (en) * | 2005-12-09 | 2007-06-14 | Cerecon Ag | Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents |
| DK2026651T3 (da) * | 2006-03-08 | 2013-07-08 | Cortria Corp | Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader |
| PL381862A1 (pl) * | 2007-02-28 | 2008-09-01 | Trigendo Spółka Z Ograniczoną Odpowiedzialnością | Zastosowanie związków pirydyniowych i sposób leczenia |
| WO2009042440A1 (en) * | 2007-09-28 | 2009-04-02 | Cortria Corporation | 1-methyl nicotinamide and derivatives for treatment of gastric injury |
| PL2211858T3 (pl) * | 2007-10-12 | 2015-06-30 | Politechnika Lodzka | Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych |
| WO2009137527A1 (en) * | 2008-05-06 | 2009-11-12 | Cortria Corporation | 1-methylnicotinamide analogs |
| WO2011047358A1 (en) * | 2009-10-15 | 2011-04-21 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| PL226999B1 (pl) * | 2013-06-11 | 2017-10-31 | Univ Jagiellonski | Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie |
-
2017
- 2017-07-16 US US16/318,257 patent/US20190282560A1/en not_active Abandoned
- 2017-07-16 EP EP17743399.2A patent/EP3484475B1/en active Active
- 2017-07-16 FI FIEP17743399.2T patent/FI3484475T3/fi active
- 2017-07-16 CN CN201780048301.3A patent/CN109562108A/zh active Pending
- 2017-07-16 WO PCT/IB2017/054293 patent/WO2018015861A1/en not_active Ceased
- 2017-07-16 PL PL17743399.2T patent/PL3484475T3/pl unknown
- 2017-07-16 AU AU2017298648A patent/AU2017298648B2/en active Active
- 2017-07-16 DK DK17743399.2T patent/DK3484475T3/da active
- 2017-07-16 ES ES17743399T patent/ES2967074T3/es active Active
- 2017-07-16 MX MX2019000721A patent/MX389845B/es unknown
- 2017-07-16 JP JP2019502239A patent/JP2019521160A/ja active Pending
- 2017-07-16 RU RU2019104343A patent/RU2744615C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3484475T3 (pl) | 2024-03-11 |
| FI3484475T3 (fi) | 2023-12-12 |
| ES2967074T3 (es) | 2024-04-25 |
| RU2019104343A3 (https=) | 2020-09-17 |
| MX2019000721A (es) | 2019-06-10 |
| US20190282560A1 (en) | 2019-09-19 |
| RU2019104343A (ru) | 2020-08-18 |
| AU2017298648B2 (en) | 2023-05-11 |
| JP2019521160A (ja) | 2019-07-25 |
| CA3030805A1 (en) | 2018-01-25 |
| DK3484475T3 (da) | 2023-11-27 |
| AU2017298648A1 (en) | 2019-01-31 |
| EP3484475B1 (en) | 2023-09-27 |
| WO2018015861A1 (en) | 2018-01-25 |
| EP3484475A1 (en) | 2019-05-22 |
| RU2744615C2 (ru) | 2021-03-11 |
| CN109562108A (zh) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389845B (es) | 1-metilnicotinamida para el tratamiento de enfermedades asociadas con la proteína c reactiva. | |
| ZA201803396B (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| PH12020551443A1 (en) | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease | |
| SG11201911929XA (en) | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | |
| CO2019006257A2 (es) | Probiotics for use in diverticulosis and diverticular disease | |
| EP3661493A4 (en) | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA | |
| EP3718561A4 (en) | Therapy for inflammatory bowel disease | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| KR102223657B9 (ko) | 염증성 장질환 예방 또는 치료용 약학적 조성물 | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| LT3820856T (lt) | C-manozido junginiai, naudingi šlapimo takų infekcijoms gydyti | |
| LT3687567T (lt) | Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką | |
| EA201792669A1 (ru) | Igfbp3 и его применение | |
| EP3331526A4 (en) | NICOTIN-DEGREEING ENZYMES FOR THE TREATMENT OF NICOTINE DEPENDENCE AND NICOTINE POISONING | |
| MX381458B (es) | Compuestos biciclicos sustituidos. | |
| PT3171174T (pt) | Lactoferrina para utilização no diagnóstico ou no prognóstico da doença de alzheimer | |
| EP3874096A4 (en) | WEAR ARRANGEMENT | |
| CY1127309T1 (el) | Ebselen για χρηση στη θεραπεια της νοσου meniep | |
| EP3866769A4 (en) | NANOCARRIAGES FOR PULMONARY INFLAMMATION THERAPY | |
| IL286818A (en) | Mirikizumab for use in a method of treating crohns disease | |
| EP3318257A4 (en) | METHOD FOR PREVENTING OR TREATING INFLAMMABLE ENDURANCE | |
| EP3492107A4 (en) | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON-BETA-RESISTANT CANCER DISEASE WITH CFLIP-SIRNA | |
| HK40063181A (en) | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | |
| EA202092133A1 (ru) | Применение антител против il-36r для лечения воспалительного заболевания кишечника |